Journals / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 2

Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Evaluation of 149 Cases

Pages
222–226
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Univariate and multivariate analyses were performed to determine independent prognostic predictors of overall survival (OS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are heterogeneous tumor groups, and they are rarely seen.
📊
Key Findings & Data:Methods: The data of 149 patients was collected retrospectively.
💡
Conclusion & Impact:Univariate and multivariate analyses were performed to determine independent prognostic predictors of overall survival (OS).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are heterogeneous tumor groups, and they are rarely seen. Our study aims to analyze the clinicopathologic, demographic, and survival features of patients with GEP-NET. Methods: The data of 149 patients was collected retrospectively. Clinicopathologic, demographic, and survival features of patients with GEP-NET were investigated. Survival analysis was performed by using the Kaplan–Meier method and compared with the log-rank test. Univariate and multivariate analyses were performed to determine independent prognostic predictors of overall survival (OS). Results: Of 149 patients with GEP-NET, 65 patients (43.6%) were female and 84 patients (56.4%) were male. The most common, primary site of GEP-NET was stomach (40.3%). It was followed by pancreas (17.4%), small bowel/appendix (16.8%), colorectal (14%), and unknown primary (11.5%), respectively. The 3- and 5-year OS rate for the entire cohort were 69% and 60%, respectively. Median OS was not calculated, but the mean OS was 66.2 months. The factors significantly affecting the OS rate were age, grade, presence of metastasis at diagnosis, tumor diameter, and Ki-67 proliferation index in the univariate analysis. However, age was only meaningful in the multivariate analysis. Conclusion: Patients with GEP-NET under 50 age who have smaller tumor diameter, lower tumor grade, Ki-67 proliferation index, and absence of metastasis at the diagnosis have more prolonged survival.

🔖

Cite This Article

DUMAN, B. B., ATA, S., KÖSECİ, T., BAYRAM, E., ÇİL, T., TAŞ, Z. A., OLGUN, P., SEYYAR, M. (2022). Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Evaluation of 149 Cases. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 2, 222–226. https://ajindex.com/articles/508530

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Oberg K. Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. Ann Oncol 1999;10:S3–8
  2. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz- Pérez JA, Martínez Del Prado MP, Alonso Orduña V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794–803
  3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72
  4. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet 1963;1:238–9
  5. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population- based study. Gastroenterology 2007;132:899–904
  6. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707–12
  7. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182–8
  8. Burnik FS, Yalçin S. NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009;55:381–5
  9. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–59
  10. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117–22
  11. Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer 2017;36:51
  12. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469–92
  13. Horton KM, Kamel I, Hofmann L, Fishman EK. Carcinoid tumors of the small bowel: a multitechnique imaging approach. AJR Am J Roentgenol 2004;182:559–67
  14. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the ıncidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335–42
  15. Zhang M, Zhao P, Shi X, Zhao A, Zhang L, Zhou L. Clinicopathological features and prognosis of ga